Paysign Q2 2026 revenue rises 48% to $28.3 million; full-year outlook raised
Paysign reported second-quarter 2026 revenue of $28.25 million, up 48.1% from a year earlier, and net income of $6.76 million, or $0.11 per diluted share, versus $1.39 million, or $0.02, in the prior-year quarter. The company raised its full-year 2026 outlook to revenue of $114.0 million to $117.0 million and Adjusted EBITDA of $35.0 million to $38.0 million. Net income includes a one-time, non-cash $990,000 fair value gain on contingent consideration tied to the Gamma acquisition.
Key points
- Q2 2026 revenue of $28.25 million, up 48.1%; pharma revenue up 88.9% to $14.65 million, plasma revenue up 21.4% to $13.04 million
- Net income of $6.76 million, or $0.11 per diluted share, versus $1.39 million, or $0.02, in Q2 2025
- Full-year 2026 outlook raised: revenue $114.0 million to $117.0 million; Adjusted EBITDA $35.0 million to $38.0 million
- Plasma center count fell by 46 over 12 months to 561; company exited quarter with $27.37 million unrestricted cash and zero bank debt
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.